Academic Appointments
- John Harris Associate Professor of Neurology
Current Administrative Positions
- Chief, Division of Neuro-Oncology
- Co-Director, Brain Tumor Center
- Associate Director for Clinical Trials, Herbert Irving Comprehensive Cancer Center
Departmental Appointments
- Department of Neurology
Division of Neuro-oncology
Board Certifications
- Neurology
Areas of Expertise
- Brain & Spinal Tumors
- Cancer Care
- Neuro-Oncology
- Acoustic Neuroma
- Anaplastic Astrocytoma
- Astrocytoma
- Brain Cancer
- Brain Metastases
- Brain Stem Glioma
- Brain Tumor
- Carcinomatous meningitis
- Chordoma
- Choroid Plexus Carcinoma
- Choroid Plexus Papilloma
- Ependymoma
- Glioblastoma
- Glioblastoma Multiforme
- Gliomas
- Hemangioblastoma
- Leptomeningeal metastases
- Medulloblastoma
- Meningioma
- Metastatic Cancer
- Mixed Glioma
- Neurofibromatosis
- Oligoastrocytoma
- Oligodendroglioma
- Second Opinion
- Spinal Cord Tumor
- Spinal Tumors
Education and Training
- MD, 1998 Columbia University College of Physicians and Surgeons
- Internship: Mount Sinai Hospital
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: Memorial Sloan-Kettering Cancer Center
Locations
CUMC/Neurological Institute of New York
710 West 168th Street
New York, NY 10032- For new and current patient appointments, call:
- (212) 342-0571
- Fax:
- (212) 342-1246
Centers / Institutes / Programs
- Herbert Irving Comprehensive Cancer Center
Provider Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Insurance Programs
Please contact the provider's office directly to verify that your particular insurance is accepted.
- Aetna [EPO, HMO, Medicare Managed Care, NYP Employee Plan, NY Signature, POS, PPO, Signature Administrators, Student Health]
- Affinity [Essential Plan, Medicaid Managed Care]
- AgeWell [Medicare Managed Care, Special Needs Plan]
- Amida Care [Special Needs Plan]
- Capital District Physician Health Plan [Capital District Physician Health Plan]
- Cigna [EPO, Great West, HMO, POS, PPO]
- Emblem/GHI [Medicare Managed Care, PPO]
- Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
- Empire Blue Cross/Blue Shield [EPO, Medicare Managed Care, PPO]
- Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
- Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
- Healthfirst [Child/Family Health Plus, Leaf (Exchange), Medicaid Managed Care, Medicare Managed Care]
- Local 1199 [Local 1199]
- MagnaCare [MagnaCare]
- Multiplan [Multiplan]
- MVP Health Care [Child/Family Health Plus, Essential Plan, HMO, Medicaid Managed Care]
- Oxford Health Plans [Freedom, Liberty]
- UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
- VNSNY CHOICE [Medicare Managed Care, SelectHealth, Special Needs Plan]
- WellCare [Medicaid Managed Care, Medicare Managed Care]
This provider accepts new patients
Appointment Phone Number: (212) 342-0571
Links
Contact Info
- 2123421246
- (212) 342-0571
Presentations
Selected Invited Presentations
- Grand Rounds, Columbia University, College of Physicians & Surgeons, Neurosurgery, July, 2001
Wireless Worries: Do Cell-phones Cause Brain Tumors? - Faculty, 4th Annual Future of Supportive Therapy in Oncology, Dallas, February, 2006
Central Nervous System Metastases - Faculty, Society for Neuro-Oncology Annual Meeting, November, 2007
The Issue of Tissue: Clinical Trial Design for Targeted Therapies in Glioma - Faculty, 2nd Annual Symposium on Gliomas & Secondary Brain Tumors, November, 2008
Update on Treatment of Recurrent Glioblastoma - Grand Rounds, Barrow Neurological Institute, Neurology, October, 2008
Glioblastoma - Faculty, Education Day, Society for Neuro-Oncology, Annual National Meeting, November, 2008
Chemotherapy for Newly Diagnosed Anaplastic Oligodendroglioma? - Faculty, Education Session, ASCO, Annual National Meeting, May, 2009
Management of Newly Diagnosed Anaplastic Oligodendroglioma - Faculty, 3nd Annual Symposium on Gliomas & Secondary Brain Tumors, November, 2009
Current Approaches to Anaplastic Oligodendroglioma - Grand Rounds, Columbia University College of Physicians & Surgeons, Neurology, Sept., 2009
Glioblastoma - Platform Presentation, Joint Meeting of the Society for Neuro-Oncology and the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors, 2009
International Retrospective Study of 1000+ Adults with Anaplastic Oligodendroglial Tumors - Grand Rounds, North Shore-LIJ Health System, Neurology, March, 2010
Glioblastoma - Grand Rounds, NYU-Post Graduate Medical School, Neurology, June, 2010
Newly Diagnosed Glioblastoma - Platform Presentation, Society for Neuro-Oncology, Annual Meeting, November, 2011
Recursive Partitioning Analysis of Prognostic Variables in Newly Diagnosed Anaplastic Oligodendroglial Tumors - Grand Rounds, Columbia University College of Physicians & Surgeons, Neurology, January 2012
Glioblastoma: Past, Present, and Future - Grand Rounds, Columbia University College of Physicians & Surgeons, Hematology Oncology, January 2012
Brain Metastases - Grand Rounds, Columbia University College of Physicians & Surgeons, Neurosurgery, March 2012
Oligodendrogliomas - Neuro-Oncology Symposium, John Theurer Cancer Center at Hackensack University Medical Center, April 2012
Glioblastoma - Faculty, Weill Cornell Brain and Spine Center, Weill Cornell Cancer Center, June 2012
Brain Tumor Biotech Summit - Discussant, Publications Scientific Session, Radiation Therapy Oncology Group, Semi-annual meeting, June 2012
Molecular Markers in High Grade Gliomas: Effects on Practice? - Invited Speaker, Society for Neuro-Oncology, Annual National Meeting, November, 2012
Anaplastic Glioma: New Challenges in the Era of Molecularly Based Treatment: PCV or Temozolomide? - Faculty, American College of Radiation Oncology Annual meeting, February 2013
Anaplastic Oligodendrogliomas: Latest treatments and controversies - Grand Rounds, Weill Cornell Medical College , Neurosurgery, March 2013
Glioblastoma: Past, Present, and Future - Invited Lecturer, Columbia University, Mailman School of Public Health, Neuroepidemiology, April 2013
Brain Tumor Epidemiology - Seminar Speaker, Columbia University College of Physicians & Surgeons, Hematology-Oncology, April 2013
Glioblastoma: Past, Present, and Future - Research Seminar Series, Columbia University College of Physicians & Surgeons, Pediatric Hematology/Oncology, April 2013
Anaplastic Oligodendrogliomas: Latest Treatments and Controversies - Grand Rounds, Columbia University College of Physicians & Surgeons, Radiation-Oncology, May 2013
Anaplastic Oligodendrogliomas: Latest Treatments and Controversies - Grand Rounds, Columbia University College of Physicians & Surgeons, Neurosurgery, May 2013
Anaplastic Oligodendrogliomas: Latest Treatments and Controversies - Faculty, Update in Neuro-Oncology, Omniprex International, March 2013
Low Grade Gliomas and Anaplastic Gliomas - Faculty, American Society for Clinical Oncology, Annual National Meeting, June 2013
Scientific Discussant, Clinical Science Symposium: The Importance of Molecular Markers in Anaplastic Gliomas - Faculty, Society for Neuro-Oncology, Annual National Meeting, November, 2013
Controversies in Neuro-Oncology: PCV vs. Temozolomide for Anaplastic Oligodendrogliomas - Faculty, Weill Cornell Brain and Spine Center, Weill Cornell Cancer Center, June 2013
Brain Tumor Biotech Summit
Teaching Responsibilities
Neurology resident didactic speaker on central nervous system tumors and metastases. Teaching attending for outpatient and inpatients in Neurology Department.
Committees / Societies / Memberships
American Medical Association, Member
American Academy of Neurology, Member
Society for Neuro-Oncology, Member
American Society of Clinical Oncology, Member
Radiation Therapy Oncology Group, Brain Committee
Society for Neuro-Oncology, Annual Meeting, Abstract Review Committee
NIH Common Terminology Criteria for Adverse Events (CTCAE) Revision Committee
United Council for Neurologic Subspecialties Board, Neuro-Oncology Representative
Voices Against Brain Cancer Medical Advisory Board
American Society of Clinical Oncology, Scientific Program Committee, CNS Track
American College of Radiation Oncology, Scientific Program Committee
Honors and Awards
- Neurology Resident Teaching Award, Memorial Sloan-Kettering Cancer Center/Weill Medical College of Cornell University
- Preuss Award in Neuro-Oncology, American Academy of Neurology
- Boyer Clinical Research Award, Memorial Sloan-Kettering Cancer Center
- Gary Lichtenstein Humanitarian Award, Voices Against Brain Cancer
NIH Grants
COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)
Aug 14 2019 - Jul 31 2025
APHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AG-881 IN SUBJECTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (P&S Industry Clinical Trial)
May 20 2020 - May 20 2025
APHASE 1B/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF BGB-290 IN COMBINATION WITH RADIATION THERAPY AND/OR TEMOZOLOMIDE IN SUBJECTS WITH FIRST-LINE OR RECURRENT/REFRACTORY GLIOBLASTOMA (P&S Industry Clinical Trial)
Aug 30 2018 - Aug 30 2023
EGFRAND RELATE BIOMARKERS N GBM, CONCORDANCE ACROSS METHODS AND MAINTENANCE OVER DISEASE ARC. (P&S Industry Clinical Trial)
Jul 13 2018 - Jul 13 2023
PHASE 3B STUDY FOR MANAGEMENT OF OCULAR SIDE EFFECTS IN SUBJECTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN (ABT-414) (P&S Industry Clinical Trial)
Jul 9 2018 - Jul 9 2023
SERVICEAGREEMENT: A TWO-PART, PHASE I/IIA DOSE-ESCALATION CLINICAL TRAIL TO DEFINE THE SAFETY, TOLERABILITY, AND OPTIMAL DOSE OF CANDIDATE GBM VACCINE VBI-1901 WITH SUBSEQUENT EXTENSION OF OPTIMAL DOSE IN (P&S Industry Clinical Trial)
Dec 6 2017 - Dec 6 2022
ATWO-PART, PHASE I/IIA DOSE-ESCALATION STUDY TO DEFINE THE SAFETY, TOLERABILITY, AND OPTIMAL DOSE OF CANDIDATE GBM VACCINE VBI-1901 WITH SUBSEQUENT EXTENSION OF OPTIMAL DOSE IN RECURRENT GBM SUBJECTS. (P&S Industry Clinical Trial)
Nov 29 2017 - Nov 29 2022
A STUDY OF RADIOLOGICALLY EVIDENT TREATMENT EFFECTS IN SUBJECTS WITH GLIOBLASTOMA MULTIFORME (GBM) (P&S Industry Clinical Trial)
May 15 2017 - May 15 2022
APHASE 2, MULTICENTER STUDY OF TESEVATINIB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
Apr 18 2017 - Apr 18 2022
APHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFLORNITHINE WITH LOMUSTINE COMPARED TO LOMUSTINE ALONE IN PATIENTS WITH ANAPLASTIC ASTROCYTOMA THAT PROGRESS/RECUR AFTER IRRADIATION AND ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY (P&S Industry Clinical Trial)
Oct 26 2016 - Oct 26 2021
GBM AGILE GLOBAL ADAPTIVE TRIAL MASTER PROTOCOL (Private)
Jun 11 2019 - Oct 3 2020
APHASE II, OPEN LABEL, MULTI-CENTER STUDY IN ADULTS WITH RECURRENT HIGH GRADE GLIOMA (Federal Gov)
Apr 9 2019 - Aug 3 2020
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2020
PHASE I/II DOSE ESCALATION TRIAL TO ASSESS SAFETY OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES IN HER2 POSITIVE BREAST CANCER (P&S Industry Clinical Trial)
Feb 4 2015 - Feb 4 2020
PHASE II TRIAL OF VELCADE? (BORTEZOMIB) IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)
Dec 11 2014 - Dec 11 2019
ARANDOMIZED, PLACEBO CONTROLLED PHASE 2B/3 STUDY OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) WITH EPIDERMAL GROWTH FACTOR R (Private)
Sep 1 2015 - Aug 31 2019
COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)
Aug 1 2014 - Jul 31 2019
COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)
Aug 1 2014 - Jul 31 2019
COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)
Aug 1 2014 - Jul 31 2019
A PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH RECURRENT SOLID TUMOR BRAIN METASTASES WHO HAVE FAILED WHOLE BRAIN RADIATION THERAPY (P&S Industry Clinical Trial)
Jul 18 2014 - Jul 18 2019
IDENTIFYING LEPTOMENINGEAL METASTASIS FROM BREAST CANCER UTILIZING A NOVEL IMMUNOCYTOCHEMICAL MICROFLUIDIC DEVICE (Federal Gov)
Jul 15 2016 - Jun 30 2019
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2019
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2019
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2019
APHASE II, TWO TIER STUDY EVALUATING THE EFFICACY AND SAFETY OF SELINEXOR (KPT 330) IN PATIENTS WITH RECURRENT GLIOBLASTOMA AFTER FAILURE OF RADIATION THERAPY AND TEMOZOLOMIDE (P&S Industry Clinical Trial)
Jun 20 2014 - Jun 20 2019
APHASE IB/II, OPEN LABEL, MULITCENTER STUDY OF INC280 IN COMBINATION WITH BUPARLISIB IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
May 14 2014 - May 14 2019
APHASE 2, MULTICENTER, OPEN-LABEL STUDY OF BGJ398 IN PATIENTS WITH RECURRENT RESECTABLE OR UNRESECTABLE GLIOBLASTOMA (P&S Industry Clinical Trial)
Mar 4 2014 - Mar 4 2019
APHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL LDE225 VERSUS TEMOZOLOMIDE IN PATIENTS WITH HH-PATHWAY ACTIVATED RELAPSED MEDULLOBLASTOMA (P&S Industry Clinical Trial)
Oct 2 2013 - Oct 2 2018
A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ABT-414 IN COMBINATION WITH RADIATION PLUS TEMOZOLOMIDE OR TEMOZOLOMIDE ALONE (P&S Industry Clinical Trial)
Aug 13 2013 - Aug 13 2018
AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PLX3397 IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (P&S Industry Clinical Trial)
Jul 26 2013 - Jul 26 2018
IDENTIFYING LEPTOMENINGEAL METASTASIS FROM BREAST CANCER UTILIZING A NOVEL IMMUNOCYTOCHEMICAL MICROFLUIDIC DEVICE (Federal Gov)
Jul 15 2016 - Jun 30 2018
PHASE II STUDY OF AMG 386 WITH AND WITHOUT BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
Apr 23 2013 - Apr 23 2018
PILOT STUDY OF EGFR INHIBITION USING HIGH DOSE ADMINISTRATION OF ERLOTINIB WEEKLY FOR RECURRENT MALIGNANT GLIOMAS WITH EGFR VARIANT III MUTATION - PILOT STUDY OF EGFR INHIBITION FOR GMB (P&S Industry Clinical Trial)
Jan 10 2013 - Jan 10 2018
A PHASE 2 STUDY OF MEDI-575 IN ADULT SUBJECTS WITH RECURRENTGLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)
Jan 5 2011 - Jan 5 2016
PHASE II CLINICAL TRIAL OF PERIFOSINE + TEMSIROLIMUS FOR RECURRENT GLIOBLASTOMA WITH TISSUE AND IMAGING CORRELATES OF RESPONSE (Private)
Jan 1 2013 - Dec 31 2015
COLUMBIA UNIVERSITY MEDICAL CENTER MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM (MB-CCOP) (Federal Gov)
Aug 6 2012 - May 31 2015
RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)
Jan 1 2009 - Dec 31 2014
PULSATILE KINASE INHIBITOR THERAPY FOR MALIGNANT GILOMA: PROOF OF CONCEPT CLINICAL TRIAL (Private)
Jun 1 2013 - May 31 2014
